Skip to main content

Pharmaceutical Technologies (PT)

The Neural Analytics Lucid™ M1 transcranial Doppler Ultrasound System is indicated as an adjunct to the standard clinical practices for measuring and displaying cerebral blood flow velocity within the major conducting arteries and veins of the head and neck. Additionally, the Lucid™ M1 System measures the occurrence of transient emboli signals within the blood stream.

Technology topic

Pharmaceutical Technologies (PT)

The Pharmaceutical Technologies topic covers a wide range of technology areas that advance the discovery, formulation, and manufacture of novel drugs, moieties, compounds, products, processes, platforms or services that will improve the selection, quality or price of pharmaceutical and biologic therapies.

The Pharmaceutical Technologies topic is not aimed at supporting or conducting clinical trials, clinical efficacy and safety studies, the development of pre-clinical or clinical-stage drug candidates, work on medical devices or schedule I substances, or work performed primarily for regulatory purposes. Limited studies with human subjects may be acceptable if they are performed in support of feasibility, proof-of-concept studies of early-stage technologies and must follow NSF policies on research on human subjects. Proposals that request support for clinical studies are noncompliant with the SBIR/STTR solicitations and returned without review.

The NSF SBIR/STTR program no longer supports the development of specific therapeutic molecules. Drug Discovery and Manufacturing are still supported by the program.

Subtopics are not aimed at supporting clinical trials, the clinical validation of information technologies, or medical devices or studies performed primarily for regulatory purposes. Limited studies with human subjects may be acceptable to the extent that they are performed in support of feasibility, such as proof-of-concept studies of early-stage technologies. Proposals that request support for clinical studies will be deemed noncompliant with the SBIR/STTR solicitations and returned without review.

Sub-Topics

PT1. Drug Discovery
PT2. Pharmaceutical and Biologic Manufacturing
PT3. Other Pharmaceutical Technologies

Program director

Erik Pierstorff headshot

Erik Pierstorff